TD Private Client Wealth LLC Has $420,000 Holdings in Quest Diagnostics Incorporated (NYSE:DGX)

TD Private Client Wealth LLC lifted its position in shares of Quest Diagnostics Incorporated (NYSE:DGX - Free Report) by 667.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,479 shares of the medical research company's stock after buying an additional 2,156 shares during the quarter. TD Private Client Wealth LLC's holdings in Quest Diagnostics were worth $420,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Bruce G. Allen Investments LLC boosted its position in Quest Diagnostics by 57.8% during the first quarter. Bruce G. Allen Investments LLC now owns 183 shares of the medical research company's stock valued at $31,000 after purchasing an additional 67 shares in the last quarter. First Horizon Advisors Inc. lifted its position in Quest Diagnostics by 76.6% during the 1st quarter. First Horizon Advisors Inc. now owns 189 shares of the medical research company's stock worth $32,000 after acquiring an additional 82 shares during the period. Golden State Wealth Management LLC boosted its position in Quest Diagnostics by 157.3% in the first quarter. Golden State Wealth Management LLC now owns 193 shares of the medical research company's stock valued at $33,000 after buying an additional 118 shares during the last quarter. NBC Securities Inc. acquired a new stake in shares of Quest Diagnostics in the first quarter worth $35,000. Finally, Continuum Advisory LLC raised its stake in shares of Quest Diagnostics by 11,100.0% during the 1st quarter. Continuum Advisory LLC now owns 224 shares of the medical research company's stock valued at $38,000 after buying an additional 222 shares during the last quarter. Hedge funds and other institutional investors own 88.06% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on DGX shares. Robert W. Baird raised their target price on Quest Diagnostics from $191.00 to $194.00 and gave the company an "outperform" rating in a research report on Wednesday, April 23rd. JPMorgan Chase & Co. lifted their price target on Quest Diagnostics from $180.00 to $190.00 and gave the stock a "neutral" rating in a report on Tuesday, May 6th. Wall Street Zen cut Quest Diagnostics from a "buy" rating to a "hold" rating in a research note on Saturday, June 7th. Redburn Atlantic began coverage on shares of Quest Diagnostics in a research note on Wednesday, April 2nd. They issued a "buy" rating and a $195.00 price target on the stock. Finally, Truist Financial raised their target price on Quest Diagnostics from $182.00 to $190.00 and gave the company a "hold" rating in a report on Wednesday, April 23rd. Eight analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $185.73.

Insider Buying and Selling

In related news, SVP Mark E. Delaney sold 874 shares of the firm's stock in a transaction on Monday, May 12th. The shares were sold at an average price of $175.72, for a total transaction of $153,579.28. Following the completion of the sale, the senior vice president directly owned 8,372 shares of the company's stock, valued at approximately $1,471,127.84. This trade represents a 9.45% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 8.16% of the company's stock.

Quest Diagnostics Price Performance

Shares of NYSE:DGX traded down $3.45 on Friday, reaching $168.00. 1,335,607 shares of the company were exchanged, compared to its average volume of 807,065. The company has a 50-day moving average of $176.08 and a 200-day moving average of $168.33. The firm has a market cap of $18.76 billion, a price-to-earnings ratio of 18.86, a price-to-earnings-growth ratio of 2.39 and a beta of 0.49. The company has a current ratio of 1.44, a quick ratio of 1.31 and a debt-to-equity ratio of 0.84. Quest Diagnostics Incorporated has a 1-year low of $137.71 and a 1-year high of $182.38.

Quest Diagnostics (NYSE:DGX - Get Free Report) last issued its quarterly earnings data on Tuesday, April 22nd. The medical research company reported $2.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.15 by $0.06. The business had revenue of $2.65 billion for the quarter, compared to the consensus estimate of $2.63 billion. Quest Diagnostics had a return on equity of 15.11% and a net margin of 8.81%. Equities analysts forecast that Quest Diagnostics Incorporated will post 9.7 earnings per share for the current fiscal year.

Quest Diagnostics Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, July 21st. Stockholders of record on Monday, July 7th will be paid a $0.80 dividend. This represents a $3.20 dividend on an annualized basis and a dividend yield of 1.90%. The ex-dividend date of this dividend is Monday, July 7th. Quest Diagnostics's dividend payout ratio is presently 40.46%.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.